

Subscription rates	1 year	2 years
Individual rate (1)	€130 (174 USD)	€240 (322 USD)
Student rate (1)	€60 (80 USD)	€112 (150 USD)
Institutional rate (1)(2)	€325 (436 USD)	€630 (844 USD)

1- For Solidarity subscription rates see the preceding page.
2- Commercial companies and institutions.

- Yes, I would like to subscribe to Prescrire International**
- Please send me a free sample issue of the French journal Prescrire**

Title: Mr Ms

Last Name:

First Name:

Address (1):

Zip: City:

Country:

Tel:

Fax:

E-Mail (must be provided):

Occupation:

working in the community, hospital, university, industry,
other (please circle)

1- Give the format of the address as it is used in your country.

I enclose a cheque for €
or USD

I pay €
or USD

by Credit card

VISA

EUROCARD/MASTERCARD

AMERICAN EXPRESS

Card number: | | | | | | | | | | | | | | | | | | | | | |

Expiry date: | | / | |

Signature:

Postage and handling charges are included in the quoted prices. Subscribers outside the European Union who are subject to value added tax (VAT) may pay the ex-tax cost: divide the full cost by 1.021. EU subscribers subject to VAT must provide us with their VAT code number.

Send your order with payment to:

Prescrire International

83 bd Voltaire - 75558 PARIS CEDEX 11 - FRANCE

Fax: + 33 1 49237648

e-mail: international@prescrire.org

website: www.english.prescrire.org

Prescrire turns 30

Founded in January 1981 by a group of French physicians and pharmacists, Prescrire is celebrating its 30th birthday.



Since its beginnings in 1981, Prescrire has grown, and grown stronger. But its *raison d'être* is still the same. Because in 2011, just as in 1981, healthcare professionals need independent, comparative and user-friendly information in order to deliver quality care to patients.

Today in France, the disaster caused by *benfluorex* (ex-Mediator^o) has caused a scandal, and rightfully so. More and more citizens are realising just how many obstacles stand in the way of quality care: the lack of independence of the public agencies in charge of evaluating drugs, pharmacovigilance left to drug companies, continuing education and information for healthcare professionals produced and funded mainly by the industry itself, public decisions in which financial interests outweigh the safety of the population, etc.

Prescrire is still funded entirely by subscribers, and still chooses to do without grants, advertising, shareholders, or sponsors.

In the coming years Prescrire will aim to:

- Increase the added value that we can bring in terms of quality care and patients' interests;
- Work with healthcare professionals during their initial training, in order to facilitate the transition to professional practice and continuing medical education;
- Encourage more nurses to join the Prescrire movement.

Finally, as we pass the 30-year milestone, we intend to make *Prescrire in English* a more powerful instrument of exchange and of continuing education, reaching beyond the French-speaking world. The *Prescrire in English* website and the new monthly frequency of *Prescrire International* are important steps in this direction, as we invite international readers to play an increasing role in Prescrire's activities in the years to come.

©Prescrire

For more information about Prescrire's history, who we are and how we work, see online : www.english.prescrire.org > About Prescrire